Navigation Links
AutoImmune Inc. Reports 2008 Third Quarter Financial Results
Date:11/7/2008

treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, the Company's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in the Company's most recent Annual Report on Form 10-KSB filed with the Securities and Exchange Commission in the section entitled "Risk Factors."

- Financial Chart Follows -

AUTOIMMUNE INC.

STATEMENT OF OPERATIONS

(Unaudited)

Three months ended Nine months ended

September 30, September 30,

2007 2008 2007 2008

Revenue $59,000 $57,000 $219,000 $225,000

Costs and expenses:

Cost of revenue 9,000 1,000 20,000 29,000

Research and

development 7,000 3,000 95,000 93,000

Selling, general

and administrative 163,000 125,000 532,000 511,000

Total costs and


'/>"/>

SOURCE AutoImmune Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
4. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
5. Dendreon Reports Third Quarter 2008 Financial Results
6. Osteotech Reports 2008 Third Quarter Financial Results
7. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
8. Oncothyreon reports third quarter 2008 financial results
9. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
10. NeurogesX Reports Third Quarter 2008 Results
11. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics, today announced that ... Global Healthcare Conference in Miami, FL at the Loews Miami ... executive officer of Pfenex, will provide an overview ... on March 12th at 9:00 am ET. A live audio webcast ...
(Date:3/2/2015)... YORK , March 2, 2015 ... scroll to bottom.   Moments ago, Analysts ... including Sunshine Heart (NASDAQ: SSH ), ... ), Syneron Medical (NASDAQ: ELOS ), Spectranetics (NASDAQ: ... ). Analysts Review provides a single unified platform for investors, ...
(Date:3/2/2015)... , March 2, 2015 VG ... developing therapies for autoimmune and infectious diseases, announced ... has issued an important new composition of matter ... through the targeting of CLIP. ... technology underlying VG Life Sciences, VG1177, a synthetic ...
(Date:3/2/2015)... March 02, 2015 Global ... formed alliance with Shenzhen HANK Bioengineering Co., Ltd. ... The alliance will establish a stem cells training ... China in September 2015. , Shenzhen HANK is ... an award-winning scientist, microbiologist and virologist, to integrate ...
Breaking Biology Technology:Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3
... BEIJING , June 29 /PRNewswire-Asia-FirstCall/ -- China ... "Company"), a leading organic,compound fertilizer manufacturer and distributor in ... $10 million as a result of the exercise ... IV, L.P. and CAGP IV,Co-Investment, L.P., two affiliates of ...
... June 29 Reportlinker.com announces that a new market ... , , ... Follow-On Biologics: Global Market Outlook 2010-2025 - opportunities and challenges ... , , ...
... "More than meets the eye" may soon become more ... toys. Researchers at Harvard and MIT have reshaped the ... on the ancient art of origami. Called programmable matter ... composed of interconnected triangular sections could transform itself into a ...
Cached Biology Technology:China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group 2China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group 3China Agritech, Inc. Receives $10 Million From Warrant Exercise by The Carlyle Group 4Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 2Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 3Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 4Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 5Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 6Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 7Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 8Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 9Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 10Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 11Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 12Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 13Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 14Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 15Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 16Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 17Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential 18Shape-shifting sheets automatically fold into multiple shapes 2
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... to many men during their fight against prostate cancer can ... The findings were published online this week in a pair ... of Sciences . The results may help explain a ... common treatment for men with advanced prostate cancer, generally keeps ...
... Additional Funding by Syncom Venture Partners and Participation ... GE Security, Baker Capital and Lehman Brothers., NEW ... airport,security, has secured $44.4 million in venture funding. Led ... second investor Syncom Venture,Partners, and existing investors Lockheed Martin, ...
... the U.S. Environmental Protection Agency (EPA) announced the award of ... to investigate how the sizes and shapes of nanoparticles affect ... largest EPA Science to Achieve Results (STAR) grant ever awarded ... single grant ever awarded by EPA STAR for nanotechnology research. ...
Cached Biology News:Why a common treatment for prostate cancer ultimately fails 2Why a common treatment for prostate cancer ultimately fails 3Why a common treatment for prostate cancer ultimately fails 4Clear(R) Secures $44.4 Million in Venture Funding 2Clear(R) Secures $44.4 Million in Venture Funding 3$2M grant awarded to University of Kentucky for research on nanoparticles and human health 2
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... Inhibitor is a potent noncompetitive ... as RNase A. Like other ... Inhibitor is an acidic protein ... kDa. RNaseOUT inhibits RNase A ...
... Inhibitor (Ribonuclease inhibitor) is a ... to inhibit RNase activity. It ... endonuclease activity. , Inhibits ... RNA template , Lacks ...
Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
Biology Products: